I see this as a very positive U-turn from the consumer businesses of years past. Reduced risk, lower barrier to entry for a conservative industry, less marketing need, cash flows in.
Do I remember @Antti_Luiro correctly about the change from the old report: Your forecast for cash flow positivity shifted a couple of years further, but at that point, there would still be 20 M€ in cash remaining. In the old forecast, the cash seemed to briefly run out.
Yes, well noted, now the cash situation clearly has more buffer. The company’s cash flow has indeed been less in the red than we expected in recent years.
Behind this has been a combination of cost efficiency (the company has managed with a lean organization) and the more significant role of (theoretical) IFRS 2 expense entries for options (these were insufficiently accounted for in our cash flow forecasts, even though options for shareholders, in certain scenarios, do bring real costs through dilution in the long term).
The South Savo Wellbeing Services County has agreed on piloting Nightingale Health’s blood analysis technology as part of the primary healthcare organized by the Wellbeing Services County. In cooperation with the South Savo Wellbeing Services County, Nightingale Health’s disease risk-identifying test will be made available to over 100,000 people.
Great news – we’ll get impressive public healthcare references. If only the other wellbeing services counties could also be secured. It’s interesting how the significance of this news is interpreted abroad and if the first fluctuations are seen on the OTC trading platform. I’m not holding my breath, but this seems to be the first major news since trading on that international trading platform opened in March.
I sold my shares a few months ago at 2.75, now back under 3 euros. My faith was restored with the agreement. Other welfare regions will surely follow suit with this.
" In addition, Inderes analyst Antti Luiro estimates that the realization of the company’s high growth potential requires continuous new commercial agreements and successful implementation by existing customers, which creates uncertainty about the speed of revenue realization."
The Salkunrakentaja article gives the impression that this is commenting ‘after the fact’, even though these are likely Luiro’s earlier comments. They are certainly still valid, but the impression that this is commenting on this news is really disturbing.
In Finland, if/when something like this is rolled out publicly, there’s no turning back. Even if the company made losses for the next 10 years, they’d find public money from somewhere to support it
Here’s the undersigned’s wonderfully outdated statement from 5 days ago from a comprehensive report
Public healthcare and integrated payer/provider systems could utilize Nightingale to build a preventive and outcomes-based healthcare system. The change would be quite colossal for a slow-moving industry, in our view, so we estimate customer wins in this segment to be further down the line.
Contracts were indeed already expected, but not from the public sector side now we are still waiting to see proper revenue growth from these contracts
“The UK Biobank, in collaboration with Nightingale Health, is analyzing 54 million protein samples from 500,000+ participants—spanning 25 years of health data.” Post | LinkedIn
That bigger deal didn’t come through for the fiscal year after all. I’d be lying if I said I wasn’t disappointed at all. Well, if it comes, it comes, let’s continue holding and enjoy the summer.